1. Home
  2. KDP vs ALNY Comparison

KDP vs ALNY Comparison

Compare KDP & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Keurig Dr Pepper Inc.

KDP

Keurig Dr Pepper Inc.

HOLD

Current Price

$25.48

Market Cap

37.4B

ML Signal

HOLD

Logo Alnylam Pharmaceuticals Inc.

ALNY

Alnylam Pharmaceuticals Inc.

HOLD

Current Price

$319.18

Market Cap

42.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KDP
ALNY
Founded
1981
2002
Country
United States
United States
Employees
N/A
115
Industry
Beverages (Production/Distribution)
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
37.4B
42.1B
IPO Year
2007
2004

Fundamental Metrics

Financial Performance
Metric
KDP
ALNY
Price
$25.48
$319.18
Analyst Decision
Buy
Strong Buy
Analyst Count
16
28
Target Price
$34.56
$471.93
AVG Volume (30 Days)
9.1M
1.0M
Earning Date
04-23-2026
04-30-2026
Dividend Yield
3.58%
N/A
EPS Growth
45.71
206.88
EPS
1.53
2.33
Revenue
$16,603,000,000.00
$1,037,418,000.00
Revenue This Year
$59.03
$52.99
Revenue Next Year
$14.33
$31.77
P/E Ratio
$16.81
$141.43
Revenue Growth
8.16
22.88
52 Week Low
$24.88
$205.87
52 Week High
$35.94
$495.55

Technical Indicators

Market Signals
Indicator
KDP
ALNY
Relative Strength Index (RSI) 31.81 47.47
Support Level $25.03 $302.52
Resistance Level $28.38 $330.33
Average True Range (ATR) 0.63 10.95
MACD -0.08 1.74
Stochastic Oscillator 24.62 54.53

Price Performance

Historical Comparison
KDP
ALNY

About KDP Keurig Dr Pepper Inc.

Keurig Dr Pepper was established in 2018 following a merger between Keurig Green Mountain Coffee and Dr Pepper Snapple. The company manufactures and distributes coffee systems (including coffee brewers and single-serve coffee pods) under the Keurig and Green Mountain brands, as well as ready-to-drink beverages including flavored (non-cola) sparkling soft drinks under well-known brands such as Dr Pepper, Snapple, and Canada Dry. The company controls production and route to market for its own brands through in-house manufacturing plants and distribution infrastructure and leverages these facilities to manufacture and distribute for third-party coffee and beverage brands via licensing and partnership agreements. The US and Canada make up 95% of revenue, with the rest from Mexico.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway in cells that enables sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Share on Social Networks: